Last reviewed · How we verify
Xalatan (LATANOPROST)
Xalatan works by increasing the outflow of fluid from the eye, reducing pressure.
Xalatan (Latanoprost) is a prostaglandin analog used to treat ocular hypertension and open-angle glaucoma. It works by targeting the prostaglandin F2-alpha receptor, increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. Originally developed by Pharmacia and Upjohn, it is now owned by Thea Pharma. Xalatan is a small molecule modality, FDA-approved in 1996, and has multiple generic manufacturers. As an off-patent medication, it is widely available.
At a glance
| Generic name | LATANOPROST |
|---|---|
| Sponsor | Thea Pharma |
| Drug class | Prostaglandin Analog [EPC] |
| Target | Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1996 |
Mechanism of action
Mechanism of Action. Latanoprost is prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Approved indications
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- upper respiratory tract infection/cold/flu
- Chest pain/angina pectoris
- muscle/joint/back pain
- rash/ allergic skin reaction
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2,PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Effect of IOP Lowering on Progressive HM (NA)
- Androgenic Alopecia TH07 Clinical Trial (PHASE3)
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 9539262 | 2028-10-15 | Method of Use |
| 9629852 | 2029-09-12 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xalatan CI brief — competitive landscape report
- Xalatan updates RSS · CI watch RSS
- Thea Pharma portfolio CI